The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, ...

Investing.com -- GlaxoSmithKline (NYSE: GSK) Bioc announced its financial results for the second quarter, reporting a consolidated net profit attributable of EGP 5.9 million. The company also reported ...

London: GSK plc has announced that a supplemental New Drug Application for gepotidacin has been accepted by the US Food and ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK plc has announced the purchase of 494,426 of its own ordinary shares as part of ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

US FDA accepts for priority review GSK’s sNDA for gepotidacin for oral treatment of uncomplicated urogenital gonorrhoea: London, UK Tuesday, August 12, 2025, 10:00 Hrs [IST] GSK ...

In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents ...

The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.

Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

GSK plc's experimental antibiotic, gepotidacin, has been granted priority review by the U.S. Food and Drug Administration ...